Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: Other
Life Threatening? No
Write-up: Information has been received from Sanofi Pasteur MSD (reference # IE-1577272925-2016006866) on 01-JUL-2016. This case was received from RA (Ref no. IE-HPRA-2016-027090) on 29-Jun-2016. Initial case received from a consumer/other non-health professional which concerns a 14-year-old female adolescent patient received GARDASIL (batch number G019345) on 20-Sep-2012, GARDASIL (batch number H008259) on 15-Nov-2012, GARDASIL (batch number H013135) on 21-Mar-2013. The patient received concomitant administration of BOOSTRIX on 21-Mar-2013. Medical history/concurrent conditions: None. The patient experienced Headaches, Dizziness, Loss of power of limbs, Nosebleeds, Blurred vision, Fatigue, Noise sensitivity, Brain fog, Vomiting and Nausea on 01-Jun-2013 72 days Post Administration. The reporter added that her daughter has lost her quality of life. She has been poorly since 2013 and to this day is no better. She was a healthy, outgoing girl involved in sports and socializing with her friends. Now most days she can hardly get out of bed. The patient''s outcome was reported as Not Recovered/Not Resolved. The reporter assessed the causal relationship between Headache, Dizziness, Weakness of limbs, Nosebleeds, Blurred vision, Fatigue, Sound sensitivity increased, Foggy feeling in head, Vomiting, Nausea and GARDASIL as Unknown.
Copyright © 2018 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166